Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma.

Rustad EH, Misund K, Bernard E, Coward E, Yellapantula VD, Hultcrantz M, Ho C, Kazandjian D, Korde N, Mailankody S, Keats JJ, Akhlaghi T, Viny AD, Mayman DJ, Carroll K, Patel M, Famulare CA, Op Bruinink DH, Hutt K, Jacobsen A, Huang Y, Miller JE, Maura F, Papaemmanuil E, Waage A, Arcila ME, Landgren O.

Am J Hematol. 2019 Oct 1. doi: 10.1002/ajh.25641. [Epub ahead of print]

PMID:
31571261
2.

Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma.

Rustad EH, Hultcrantz M, Yellapantula VD, Akhlaghi T, Ho C, Arcila ME, Roshal M, Patel A, Chen D, Devlin SM, Jacobsen A, Huang Y, Miller JE, Papaemmanuil E, Landgren O.

PLoS One. 2019 Mar 22;14(3):e0211600. doi: 10.1371/journal.pone.0211600. eCollection 2019.

3.

Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients.

Kazandjian D, Hill E, Hultcrantz M, Rustad EH, Yellapantula V, Akhlaghi T, Korde N, Mailankody S, Dew A, Papaemmanuil E, Maric I, Kwok M, Landgren O.

Blood Cancer J. 2019 Feb 4;9(2):15. doi: 10.1038/s41408-019-0177-9.

4.

PD1 is expressed on exhausted T cells as well as virus specific memory CD8+ T cells in the bone marrow of myeloma patients.

Sponaas AM, Yang R, Rustad EH, Standal T, Thoresen AS, Dao Vo C, Waage A, Slørdahl TS, Børset M, Sundan A.

Oncotarget. 2018 Aug 10;9(62):32024-32035. doi: 10.18632/oncotarget.25882. eCollection 2018 Aug 10.

5.

Monitoring multiple myeloma by quantification of recurrent mutations in serum.

Rustad EH, Coward E, Skytøen ER, Misund K, Holien T, Standal T, Børset M, Beisvag V, Myklebost O, Meza-Zepeda LA, Dai HY, Sundan A, Waage A.

Haematologica. 2017 Jul;102(7):1266-1272. doi: 10.3324/haematol.2016.160564. Epub 2017 Apr 6.

6.

BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis.

Rustad EH, Dai HY, Hov H, Coward E, Beisvag V, Myklebost O, Hovig E, Nakken S, Vodák D, Meza-Zepeda LA, Sandvik AK, Wader KF, Misund K, Sundan A, Aarset H, Waage A.

Blood Cancer J. 2015 Mar 20;5:e299. doi: 10.1038/bcj.2015.24.

Supplemental Content

Loading ...
Support Center